914636-35-4 Usage
Uses
Used in Pharmaceutical Industry:
3-Bromo-5-(trifluoromethoxy)aniline is used as a key intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into the molecular structures of various medicinal compounds. Its unique properties allow it to contribute to the development of new drugs with specific therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Bromo-5-(trifluoromethoxy)aniline serves as an intermediate in the production of agrochemicals. Its reactivity and stability make it suitable for the creation of compounds that can be used in pesticides, herbicides, and other agricultural products to enhance crop protection and yield.
Used in Dye Industry:
3-Bromo-5-(trifluoromethoxy)aniline is utilized as a starting material in the synthesis of dyes. Its chemical structure allows for the development of dyes with specific color properties and stability, which are essential for various applications in textiles, printing, and other industries that rely on colorants.
Used in Organic Synthesis:
3-Bromo-5-(trifluoromethoxy)aniline is used as a versatile building block in organic synthesis. Its unique reactivity enables it to undergo a wide range of chemical reactions, making it an invaluable component in the creation of new organic compounds for research and commercial applications.
Check Digit Verification of cas no
The CAS Registry Mumber 914636-35-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,4,6,3 and 6 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 914636-35:
(8*9)+(7*1)+(6*4)+(5*6)+(4*3)+(3*6)+(2*3)+(1*5)=174
174 % 10 = 4
So 914636-35-4 is a valid CAS Registry Number.
914636-35-4Relevant academic research and scientific papers
NEW CHEMICAL COMPOUNDS
-
Page/Page column 90, (2009/03/07)
The present invention encompasses compounds of general formula (1), wherein the groups R1 to R3 and L are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for
